Close Menu

NEW YORK – CytoDyn announced Friday that based on the continued promising activity seen in early investigations of its CCR5 antagonist leronlimab in molecularly defined subsets of metastatic breast cancer patients, the company wants to rapidly expand enrollment in the clinical trial and enroll patients with other kinds of solid tumors.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.